PDL BioPharma, Inc. (PDLI) financial statements (2021 and earlier)

Company profile

Business Address 59 DAMONTE RANCH PARKWAY
RENO, NV 89521
State of Incorp. DE
Fiscal Year End December 31
SIC 2836 - Biological Products, Except Diagnostic Substances (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

8/31/2020
Q4
6/30/2020
Q2
3/31/2020
Q1
12/31/2019
Q3
9/30/2019
Q3
6/30/2019
Q2
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments 105126169294285
Cash and cash equivalents 105126169294285
Receivables 5353536363
Inventory, net of allowances, customer advances and progress billings 131182116
Inventory 131182116
Disposal group, including discontinued operation 28933370  
Other undisclosed current assets 3530142835
Total current assets: 496551314407400
Noncurrent Assets
Property, plant and equipment 33377
Long-term investments and receivables 11111
Accounts and financing receivable, after allowance for credit loss 11111
Capital leases, lessor balance sheet, net investment in direct financing and sales type leases1
Intangible assets, net (including goodwill) 1313134750
Intangible assets, net (excluding goodwill) 1313134750
Disposal group, including discontinued operation, noncurrent assets   377  
Other noncurrent assets 92192229
Other undisclosed noncurrent assets  71 381404
Total noncurrent assets: 25109403458491
TOTAL ASSETS: 521660717865890
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities 1817154138
Accounts payable 4531315
Accrued liabilities 1412122823
Taxes payable    00
Disposal group, including discontinued operation 182531  
Total current liabilities: 3642464138
Noncurrent Liabilities
Long-term debt and lease obligation 141327132129
Long-term debt, excluding current maturities 141327132129
Liabilities, other than long-term debt, including: 5152515458
Accounts payable and accrued liabilities    1111
Deferred tax liabilities, net1014
Liability for uncertainty in income taxes    3332
Disposal group, including discontinued operation, liabilities   0  
Other liabilities 51525111
Other undisclosed liabilities, other than long-term debt    00
Total noncurrent liabilities: 646578187187
Total liabilities: 101107124228225
Stockholders' equity
Stockholders' equity attributable to parent 420553593637665
Common stock 11111
Treasury stock, value  (2)  (1)
Additional paid in capital (66)(67)(79)(100)(94)
Retained earnings 485621671737759
Stockholders' equity attributable to noncontrolling interest(0)(0)(0)000
Other undisclosed stockholders' equity426     
Total stockholders' equity:425420553593637665
TOTAL LIABILITIES AND EQUITY:425521660717865890

Income statement (P&L) ($ in millions)

8/31/2020
Q4
6/30/2020
Q2
3/31/2020
Q1
12/31/2019
Q3
9/30/2019
Q3
6/30/2019
Q2
Revenues 56 44(23)
Cost of revenue (3)(3) (15)(12)
Gross profit: 33 29(35)
Operating expenses (16)(35)(11)(35)(27)
Other undisclosed operating income    1512
Operating income (loss): (14)(32)(11)9(50)
Nonoperating income (expense) (0)(14) (29)44
Investment income, nonoperating 01 547
Debt instrument, convertible, beneficial conversion feature 0    
Interest and debt expense (0)(1) (4)(3)
Other undisclosed income from continuing operations before equity method investments, income taxes 01 43
Loss from continuing operations before income taxes: (14)(46)(11)(20)(6)
Income tax benefit 114 21
Loss from continuing operations: (13)(32)(11)(18)(5)
Loss from discontinued operations (37)(0)   
Net loss: (50)(32)(11)(18)(5)
Net income attributable to noncontrolling interest 00   
Other undisclosed net income attributable to parent    00
Net loss available to common stockholders, diluted: (50)(32)(11)(18)(4)

Comprehensive Income ($ in millions)

8/31/2020
Q4
6/30/2020
Q2
3/31/2020
Q1
12/31/2019
Q3
9/30/2019
Q3
6/30/2019
Q2
Net loss: (50)(32)(11)(18)(5)
Comprehensive loss: (50)(32)(11)(18)(5)
Comprehensive income, net of tax, attributable to noncontrolling interest 00 00
Comprehensive loss, net of tax, attributable to parent: (50)(32)(11)(18)(4)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: